SYN-115 is a potent and selective inhibitor of the adenosine A2a receptor, which modulates the effect of dopamine, glutamine and serotonin in specific regions of the brain. In preclinical models of Parkinson's disease, A2a inhibition reverses motor deficits and potentiates the effect of L-dopa and dopamine agonists without inducing dyskinesias (involuntary movements). SYN-115 also displays activity in preclinical models of depression, cognition, and anxiety. Recently, there has been clinical validation of the target in improving motor symptoms.

Synosia has completed a Phase IIa study in Parkinson’s patients with SYN-115 showing functional activity in relevant regions of the brain assessed using fMRI and positive effects on clinical measures of motor function and cognition. Synosia is planning to start a Phase IIb study.